AIM OF THE STUDY: Investigate the effect of Rosuvastatin on serum level of Vaspin and Visfatin in patients with CAD and determine the association between those adipokines and the severity of CAD.
BACKGROUND: Statin treatment is considered one of the most effective strategies for the stabilization of atherosclerotic plaques and is related with enhancements in result in patients with coronary course diseases (CAD). Vaspin and Visfatin are adipokines involved in atherosclerosis progression. Objective: assess the impact of Rosuvastatin on serum level of Vaspin and Visfatin in patients with CAD and the relationship of those adipokines with seriousness of CAD.
SETTING: Cardiology department, Tanta University Hospital, Egypt. METHODS: 80 patients who underwent coronary angiography due to symptoms of stable angina were enrolled in the study. 40 patients received Rosuvastatin 20 mg/day was compared to another 40 patients, as a control group, who refused statin treatment and preferred lifestyle modifications intervention. Main outcome measure: Clinical parameters, lipid profile, troponin I, high-sensitivity C-reactive protein (hs-CRP), Vaspin and Visfatin levels were assayed at the beginning and after 3 months. CAD severity was assessed by the Gensini score.
RESULTS: Rosuvastatin administration considerably ameliorated most lipid parameters. Moreover, a significant increase of Vaspin and decrease of Visfatin concentrations (p<0.001) after Rosuvastatin treatment were observed (from 2.81 ± 0.74 ng/ml to 4.26 ± 0.76 ng/ml, from 4.62 ± 0.76 to 3.13 ± 0.98 respectively). There was a negative correlation between Vaspin and the Gensini score and positive correlation between Visfatin and Gensini score (r=-0.18 and r=0.19, p=0.05, respectively).
CONCLUSION: Rousvastatin treatment reduces serum visfatin and increase serum vaspin levels in CAD patients. Those effects of Rousvastatin are of clinical importance.
